Free 1 week trial

Add Alert

My Alerts

My Favorites

Start for free now

Contract Details

Title	Identifying High Carbon Footprint Medicines United Kingdom
You can sign up and unlock it for free Access to Public and Private Sector Business Opportunities for 200+ Countries Subscribe now Already a member? Sign in now!
Country	United Kingdom
Language	English
Organization	NHS England & NHS Improvement
Published Date	12.03.2024
Awarded Date	08.02.2022
Overview	Contract Award's Details : Identifying High Carbon Footprint Medicines NHS England & NHS Improvement Identifying High Carbon Footprint Medicines Need for the project 1. The 2019 NHS Long Term Plan set sustainability commitments for the NHS, which are elaborated in the & 039;Delivering a Net Zero National Health Service& 039; report. 2. The 2020 & 039;Delivering a Net Zero National Health Service& 039; report committed the NHS to reaching net zero carbon emissions across the emissions that it directly controls by 2040 (with an 80% reduction by 2032) and for its full scope, including its supply chain, by 2045 (with an 80% reduction by 2039). Medicines account for 25% of NHS carbon emissions, 5 percentage points being direct emissions, e.g. from inhalers and anaesthetic gases, and 20% being from other medicines, including those emissions embedded in the medicines supply chain. 3. Whilst several options exist, it is unclear which methodology is the most practical and usable for the NHS in assessing the carbon footprint of specific medicines, which is essential for determining the next steps in the NHS& 039;s strategy to reduce emissions from medicines, particularly those beyond direct emissions from inhalers and anaesthetics. Example of options considered to date: â€¢ Process mass intensity (PMI) is one methodology of assessing the environmental impact of chemical and pharmaceutical development processes. PMI uses the total mass of input materials required to produce a unit of the target chemical product. It has the advantage of being relatively easy to calculate, where the manufacturing process data is readily available, but has the limitation of being a proxy and still requires manufacturing information â€¢ Top down economic modelling of medicine supply chains assumes the same intensity of carbon emissions per unit of monetary value. This homogeneity assumption is a well-known limitation of input/output modelling. 4. There is limited information available on emissions from active pharmaceutical ingredients (APIs) and the manufacture of them. It is important to note that the API is only one component that contributes to the emissions of medicine manufacturing - many other chemicals and processes could be used in medicine manufacture, which must also be included in the assessment of emissions per medicine. 5. There are broader impacts of the production and manufacture of medicines on the environment. The focus of this methodology must be carbon emissions (CO2e), but broader environmental impacts should also be considered to avoid unintended environmental consequences. 6. A number of factors must be taken into account when defining medicines related policy measures to reduce carbon emissions. It is critical that any change in policy results in no diminution in patient outcome (ideally an improvement in patient outcomes will be realised). Other factors such as financial impact or supply chain resilience must also be considered. The objective of this project is therefore to understand the best approach to assess carbon emissions from specific medicines or groups of medicines (e.g. by class) United Kingdom Contract value : 48,000.00 GBP Contractors : Carbon Trust Advisory Limited 10/02/2022 09/02/2022 10/05/2022 78096579 09/02/2022 NHS England & NHS Improvement Address : Quarry House LS2 7UE, Leeds Andrew Powell andrew.powell14@nhs.net 07970786424 United Kingdom United Kingdom Contract Awards United Kingdom ocds-b5fd17-c7768404-b9c7-4da9-9df8-1ed2d0455aa8-508497-cf-0628600d0o000000rwimuaa1 10/02/2022 10/05/2022 48,000.00 GBP
NAICS	Navigational Other Direct Insurance (except Life Electric Power Transmission Mining Regulation and Administration of Communications Motorcycle Trust Direct Insurance (except Life Regulation and Administration of Communications Direct Life Measuring Navigational Trusts Photographic Film Environment Trusts Process Funds
CPVS	Anaesthetics Gases Control, safety, signalling and light equipment Control, safety or signalling equipment for inland waterways Carbon Control, safety or signalling equipment for parking facilities Command, control, communication systems Control, safety or signalling equipment for port installations Machinery for mining, quarrying, construction equipment Command, control, communication and computer systems Installation services of mining, quarrying, construction and metallurgy machinery Parts of chain Chain Pressure-reducing, control, check or safety valves Other services Control, safety or signalling equipment for roads Control, safety or signalling equipment for airports Dates
UNSPSC	-
Regions	Europe Northern Europe
Sectors	Chemicals Healthcare and Medicine Environment and Pollution-Recycling Automobiles and Auto Parts Supply Minerals and Mining Bridges and Tunnels Roads and Highways-Bridge Oil and Gas Environmental Work Railways-Rail-Railroad Defence and Security Construction Consultancy Energy-Power and Electrical Computer Hardwares and Consumables Pharmaceuticals
Contractor	Carbon Trust Advisory Limited
Contract Value	48,000.00 GBP
URL	Download Document
Share

Title
Identifying High Carbon Footprint Medicines United Kingdom
Country
United Kingdom
Language
English
Organization
NHS England & NHS Improvement
Published Date
12.03.2024
Awarded Date
08.02.2022
Overview
Contract Award's Details : Identifying High Carbon Footprint Medicines NHS England & NHS Improvement Identifying High Carbon Footprint Medicines Need for the project 1. The 2019 NHS Long Term Plan set sustainability commitments for the NHS, which are elaborated in the & 039;Delivering a Net Zero National Health Service& 039; report. 2. The 2020 & 039;Delivering a Net Zero National Health Service& 039; report committed the NHS to reaching net zero carbon emissions across the emissions that it directly controls by 2040 (with an 80% reduction by 2032) and for its full scope, including its supply chain, by 2045 (with an 80% reduction by 2039). Medicines account for 25% of NHS carbon emissions, 5 percentage points being direct emissions, e.g. from inhalers and anaesthetic gases, and 20% being from other medicines, including those emissions embedded in the medicines supply chain. 3. Whilst several options exist, it is unclear which methodology is the most practical and usable for the NHS in assessing the carbon footprint of specific medicines, which is essential for determining the next steps in the NHS& 039;s strategy to reduce emissions from medicines, particularly those beyond direct emissions from inhalers and anaesthetics. Example of options considered to date: â€¢ Process mass intensity (PMI) is one methodology of assessing the environmental impact of chemical and pharmaceutical development processes. PMI uses the total mass of input materials required to produce a unit of the target chemical product. It has the advantage of being relatively easy to calculate, where the manufacturing process data is readily available, but has the limitation of being a proxy and still requires manufacturing information â€¢ Top down economic modelling of medicine supply chains assumes the same intensity of carbon emissions per unit of monetary value. This homogeneity assumption is a well-known limitation of input/output modelling. 4. There is limited information available on emissions from active pharmaceutical ingredients (APIs) and the manufacture of them. It is important to note that the API is only one component that contributes to the emissions of medicine manufacturing - many other chemicals and processes could be used in medicine manufacture, which must also be included in the assessment of emissions per medicine. 5. There are broader impacts of the production and manufacture of medicines on the environment. The focus of this methodology must be carbon emissions (CO2e), but broader environmental impacts should also be considered to avoid unintended environmental consequences. 6. A number of factors must be taken into account when defining medicines related policy measures to reduce carbon emissions. It is critical that any change in policy results in no diminution in patient outcome (ideally an improvement in patient outcomes will be realised). Other factors such as financial impact or supply chain resilience must also be considered. The objective of this project is therefore to understand the best approach to assess carbon emissions from specific medicines or groups of medicines (e.g. by class) United Kingdom Contract value : 48,000.00 GBP Contractors : Carbon Trust Advisory Limited 10/02/2022 09/02/2022 10/05/2022 78096579 09/02/2022 NHS England & NHS Improvement Address : Quarry House LS2 7UE, Leeds Andrew Powell andrew.powell14@nhs.net 07970786424 United Kingdom United Kingdom Contract Awards United Kingdom ocds-b5fd17-c7768404-b9c7-4da9-9df8-1ed2d0455aa8-508497-cf-0628600d0o000000rwimuaa1 10/02/2022 10/05/2022 48,000.00 GBP
NAICS
Navigational Other Direct Insurance (except Life Electric Power Transmission Mining Regulation and Administration of Communications Motorcycle Trust Direct Insurance (except Life Regulation and Administration of Communications Direct Life Measuring Navigational Trusts Photographic Film Environment Trusts Process Funds
CPVS
Anaesthetics Gases Control, safety, signalling and light equipment Control, safety or signalling equipment for inland waterways Carbon Control, safety or signalling equipment for parking facilities Command, control, communication systems Control, safety or signalling equipment for port installations Machinery for mining, quarrying, construction equipment Command, control, communication and computer systems Installation services of mining, quarrying, construction and metallurgy machinery Parts of chain Chain Pressure-reducing, control, check or safety valves Other services Control, safety or signalling equipment for roads Control, safety or signalling equipment for airports Dates
UNSPSC
-
Regions
Europe Northern Europe
Sectors
Chemicals Healthcare and Medicine Environment and Pollution-Recycling Automobiles and Auto Parts Supply Minerals and Mining Bridges and Tunnels Roads and Highways-Bridge Oil and Gas Environmental Work Railways-Rail-Railroad Defence and Security Construction Consultancy Energy-Power and Electrical Computer Hardwares and Consumables Pharmaceuticals
Contractor
Carbon Trust Advisory Limited
Contract Value
48,000.00 GBP
URL
Download Document
Share